Relevant conflicts of interest/financial disclosures: A.P.S. is supported by the Canada Research Chair program and the E.J. Safra Foundation. N.J.R is supported by the Parkinson Society Canada.
Version of Record online: 4 OCT 2012
Copyright © 2012 Movement Disorder Society
Volume 27, Issue 12, pages 1484–1492, October 2012
How to Cite
Ray, N. J. and Strafella, A. P. (2012), The neurobiology and neural circuitry of cognitive changes in Parkinson's disease revealed by functional neuroimaging. Mov. Disord., 27: 1484–1492. doi: 10.1002/mds.25173
Full financial disclosures and author roles may be found in the online version of this article.
- Issue online: 18 OCT 2012
- Version of Record online: 4 OCT 2012
- Manuscript Accepted: 3 AUG 2012
- Manuscript Revised: 29 JUN 2012
- Manuscript Received: 11 MAY 2012
- Canadian Institutes of Health Research. Grant Number: MOP 110962
- executive functions;
Patients with Parkinson's disease (PD) often develop a spectrum of cognitive symptoms that can evolve into dementia. Dopamine (DA) replacement medications, though improving motor symptoms, can exert both positive and negative effects on cognitive ability, depending on the severity of the disease and the specific skill being tested. By considering the behavioral and clinical aspects of disease- and treatment-mediated changes in cognition alongside the pathophysiology of PD, an understanding of the factors that govern the heterogeneous expression of cognitive impairment in PD is beginning to emerge. Here, we review the neuroimaging studies revealing the neural correlates of cognitive changes after DA loss and DA replacement as well as those that may accompany the conversion from milder stages of cognitive impairment to frank dementia. © 2012 Movement Disorder Society